Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model.
Candida albicans biofilms complicate the treatment of infected implanted intravascular devices because of decreased antifungal susceptibility. In our investigation, 48 rabbits with experimental central venous catheter C. albicans infection were equally allocated to a control arm or to receive amphotericin B deoxycholate or caspofungin treatment while undergoing systemic and intraluminal lock therapy for 7 days. C. albicans was cultured from catheters from all control rabbits, from 3 that received amphotericin B, and from 0 that received caspofungin. Differences in colony counts were detected between the control and amphotericin (P<.001) and control and caspofungin (P<.001) arms. Caspofungin may be useful in the treatment of C. albicans biofilm-associated intravascular catheter infections, which warrants further study.
Shuford
Jennifer A
JA
Department of Medicine, Division of Infectious Diseases, Mayo Clinic College of Medicine, Rochester, 55905, USA.
Rouse
Mark S
MS
Piper
Kerryl E
KE
Steckelberg
James M
JM
Patel
Robin
R
D000666:Amphotericin B / Q000494:pharmacology*; D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology*; D018441:Biofilms / Q000187:drug effects*; D002176:Candida albicans / Q000187:drug effects* / Q000254:growth & development*; D000077336:Caspofungin; D002405:Catheterization, Central Venous / Q000009:adverse effects*; D003840:Deoxycholic Acid / Q000494:pharmacology*; D004338:Drug Combinations; D054714:Echinocandins; D055666:Lipopeptides; D023421:Models, Animal; D010456:Peptides, Cyclic / Q000494:pharmacology*; D011817:Rabbits
D000935:Antifungal Agents; D004338:Drug Combinations; D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; D003840:Deoxycholic Acid; D000666:Amphotericin B; C059765:amphotericin B, deoxycholate drug combination; D000077336:Caspofungin